CG Invites Co., Ltd. Overview
CG Invites is a small-cap KOSDAQ company in the middle of a deliberate transition. It is moving from first-generation Korean drug-discovery biotech (CrystalGenomics, the first company listed on KOSDAQ under the technology-evaluation special listing track in 2006) to a data-driven digital healthcare business. The transition is directed by its private-equity controlling shareholder, New Lake Alliance. The legacy asset base includes Acelex (polmacoxib), approved in 2015 as Korea's 22nd domestically developed new drug, and a clinical oncology pipeline anchored by ivaltinostat (CG-745, HDAC inhibitor, US Phase 2 in metastatic pancreatic cancer) and Korean rights to camrelizumab (PD-1). Since 2023, management has sold non-core holdings, cut R&D spending sharply, and consolidated externally sourced businesses. In FY2025 these were AI healthcare solutions, heating patches, automation equipment and genomic analysis, which together accounted for about 92% of revenue. The investment case now depends on whether the "Invites Loop" AI health platform generates revenue, including through a September 2026 China license. It also depends on resolving a US legal dispute with the founder over the ivaltinostat subsidiary, and on refinancing a negative working-capital position.
Company's own description
Third-party filings indexes summarize the company's self-description as follows. CG Invites is a biopharmaceutical company focused on digital genomics and personalized medicine, with four activity areas:
-
Genomics, using whole-genome sequencing.
-
mRNA-based personalized cancer vaccines.
-
Digital therapeutics (software-based interventions).
-
Chemical and biological drug development, covering oncology and inflammation (Acelex, ivaltinostat, camrelizumab).
Management has described the change in direction more explicitly. A company official told Dealsite TV in May 2026 that since joining the Invites ecosystem in 2023, the company has been shifting toward digital healthcare. The official said the legacy pipeline cannot be wound down all at once, but the digital-healthcare direction has become concrete since 2025.
Independent characterization
On the evidence of FY2025 revenue composition, CG Invites is now best described as a diversified small-cap healthcare holding-type company. It has a residual drug-development pipeline and a nascent AI health-data platform. FY2025 consolidated revenue by product, as reported in the DART annual report and cited by Dailypharm on 8 May 2026:
-
AI healthcare solutions: KRW 8.2bn (30.7%)
-
Heating patches (hot packs): KRW 7.2bn (27.1%)
-
Automation equipment: KRW 4.7bn (17.5%)
-
Genomic analysis and other: KRW 4.6bn (17.4%)
-
Arthritis analgesic/anti-inflammatory (Acelex): KRW 1.7bn (6.3%)
Prescription pharmaceuticals therefore contributed only about 6% of revenue. Standalone (parent-only) revenue in FY2025 was about KRW 11.8bn (Dealsite, 28 Sep 2026). This implies that roughly KRW 15.6bn, or about 57% of consolidated revenue, came from consolidated subsidiaries and businesses incorporated through acquisition or merger. Dealsite TV (May 2026) attributes the revenue growth to externally incorporated businesses and mergers rather than to in-house drug development. The specific entities that brought the heating-patch and automation-equipment businesses are not identified in the sources reviewed.
Business and revenue model
| Revenue stream | Model | Evidence |
|---|---|---|
| Acelex (polmacoxib 2mg) | Product sales (prescription drug, Korea), plus pursuit of export licensing (Russia in negotiation as of Jul 2025) | Dailypharm; Dealsite |
| AI healthcare solutions / Invites Loop | Solution/service revenue in Korea, plus technology licensing abroad: China exclusive license with a 5% running royalty on net sales (Sep 2026); planned US licensing via a New Lake Singapore hub | Dailypharm; Dealsite |
| Genomic analysis (NGS testing) | Testing-service fees. The service launched in April 2025 and received College of American Pathologists (CAP) accreditation in May 2025. | Financial News; Dailypharm |
| Heating patches | Consumer/industrial product sales | Dailypharm (DART segment data) |
| Automation equipment | Equipment sales | Dailypharm (DART segment data) |
| Pipeline out-licensing | Upfront payments and milestones (historically CG-806 with Aptose, worth up to about KRW 487bn in total). Dealsite TV reports that technology-fee income has dried up. | Dailypharm; Dealsite TV |
Value-chain position and customers
Pharmaceuticals: originator and licensor. Acelex is sold to the Korean prescription market (hospitals and clinics). Clinical development is done through CROs and outsourced research, which was cut from KRW 3.6bn in 2024 to KRW 0.5bn in 2025 (Dailypharm).
Digital health: platform/IP owner and licensor. The company acts as licensor through joint ventures (VISTA Invites Digital Ward Ltd, Hong Kong) and intends to keep IP-holder status for US expansion via New Lake Singapore (Dealsite, Jan 2026).
Customer types: hospitals and health-screening institutions (for example, the KMI partnership of Jun 2026), corporate health programs and insurers (via VISTA in China), pharmaceutical licensees, and consumer and industrial buyers for heating patches and automation equipment.
End-markets: Korean prescription NSAIDs, oncology (pancreatic cancer, NSCLC, hematologic cancers), precision genomics, AI preventive healthcare and chronic-disease management, China digital health, and consumer warming products.
Strategy
Stated strategy (paraphrased from management statements)
When joining the Invites ecosystem in June 2023, management set out three pillars, which co-CEO Oh reaffirmed in July 2025:
-
Selection and focus in the drug pipeline. Concentrate on camrelizumab and ivaltinostat, with oncology as the therapeutic focus across small molecules, genomics and digital therapeutics. Add an open in-licensing platform with biotech funds.
-
Sell non-core assets to fund clinical investment without further equity raises.
-
Install a new growth engine in data-driven, personalized digital healthcare.
Plus a shareholder-friendly, ESG-oriented governance commitment (Dailypharm, Jun 2023).
The company's stated long-term ambition is an enterprise value of KRW 1 trillion (Dailypharm, Nov 2024), against a current market capitalization of about KRW 67bn.
Initiatives announced in the last 24 months
| Date | Initiative | Detail / targets |
|---|---|---|
| Apr 2025 | Genomic testing service launch | Expected to contribute from Q2 2025 (Financial News) |
| May 2025 | CAP accreditation for NGS | Supports international credibility of testing |
| May 2025 | Personalized cancer vaccine | ASCO 2025 data with HLB; colorectal and lung indications; clinic entry as early as early 2027 |
| Jul 2025 | Acelex export pivot | Negotiations with a Russian pharmaceutical company |
| Sep 2025 | Guam hospital (GRMC) | Largest shareholder acquired control. The plan is a smart hospital and US digital-health beachhead combining HealthConnect solutions with genomic AI services (Dailypharm, May 2026). |
| Jan 2026 | Singapore hub | US licensing of Invites Loop via New Lake Singapore, to limit direct exposure to US regulatory, litigation and tax risk |
| H1 2026 | K-Digital Healthcare Alliance | Launched by the Invites ecosystem; 55 participating organizations (Dealsite) |
| Jun 2026 | KMI partnership | Joint program with Korea Medical Institute (8 screening centers, about 1.5M screenings a year) for global expansion of K-digital healthcare |
| Jun 2026 | No reverse stock split | Management chose to prove value through business results instead. All-employee stock options planned. |
| Sep 2026 | China entry | VISTA JV (17 Sep) and exclusive license to VIDW (28 Sep): 5% royalty, technology valued at about USD 6.88M. Leverages VISTA's network: Beijing clinic (~80,000 outpatients a year), Shenzhen clinic (~20,000 a year), about 30 corporate medical facilities, corporate clients including Huawei, CNPC, CNOOC, Shanghai Disneyland and Volkswagen China, and about 60 insurers. |
| 2024–2026 | e-CRO platform | Building a decentralized clinical trial platform (Dailypharm) |
Guidance and medium-term targets
-
No quantitative revenue or margin guidance is disclosed in the sources reviewed.
-
Management expected digital healthcare to monetize in earnest in H2 2026 (Dealsite, Jun 2026).
-
Medium-term target: an enterprise value of KRW 1 trillion (aspirational, no date).
-
ESG and emissions commitments: none disclosed.
Products & Services
Commercial pharmaceuticals
Acelex (polmacoxib 2 mg)
Description: Oral NSAID for osteoarthritis pain and inflammation. Polmacoxib is described as a selective COX-2 inhibitor with carbonic anhydrase affinity.
Approval/launch: Approved and launched in Korea in 2015 as Korea's 22nd domestic new drug (Dailypharm).
Target customer: Prescribers treating osteoarthritis in Korea, with export markets being pursued.
Commercial performance: KRW 2.5bn in launch year 2015 (IB Tomato). KRW 1.7bn in FY2025, equal to 6.3% of revenue (Dailypharm). Co-CEO Oh Soo-yeon acknowledged weak sales due to limited sales and marketing capability and said the company was pivoting to exports, with negotiations under way with a Russian pharmaceutical company (Dealsite, Jul 2025).
Line extension: A polmacoxib/tramadol hydrochloride combination appears in Synapse's pipeline listing.
Pricing: Not publicly disclosed.
Clinical pipeline — oncology
| Asset | Mechanism | Indication(s) | Stage (latest reported) | Partner / structure | Source |
|---|---|---|---|---|---|
| Ivaltinostat (CG-745) | HDAC inhibitor (HDAC 1, 2, 3, 6, 10) | Metastatic pancreatic ductal adenocarcinoma (maintenance with capecitabine after ≥4 months of fluoropyrimidine/FOLFIRINOX first-line therapy without progression) | Phase 2 randomized portion (NCT05249101), target 52 patients, primary endpoint PFS; about 20 US hospitals (Jan 2026) | CG Pharmaceuticals (US) | PR Newswire; Dealsite; Dailypharm |
| Ivaltinostat | HDAC inhibitor | Myelodysplastic syndrome | Phase 2 (per S&P description) | — | StockAnalysis/S&P |
| Ivaltinostat | HDAC inhibitor | AML, hepatocellular carcinoma | Preclinical | — | StockAnalysis/S&P |
| Ivaltinostat | HDAC inhibitor | Fibrotic and metabolic diseases | Phase 1 (per S&P) | — | StockAnalysis/S&P |
| Camrelizumab (SHR-1210) | Anti-PD-1 monoclonal antibody (originated in China) | Non-squamous NSCLC, EGFR/ALK wild-type, stage IIIB–IV | Korean bridging study (described as Phase 3 by S&P). 35 patients enrolled at 8 sites as of Jan 2026; Samsung Medical Center added as a site. | Korean rights held by CG Invites | Synapse; Dealsite; Dailypharm |
| Luxeptinib (CG-806) | Dual FLT3/BTK multi-kinase inhibitor | AML, CLL, non-Hodgkin lymphoma | Phase 1 historically. Not in active development per Aptose's 2026 merger filing. | Licensed to Aptose (2016; up to ~KRW 487bn). Edaily (Oct 2026) lists it among licensed Korean assets returned in 2026. | Dailypharm; Edaily/Nate |
| Personalized neoantigen cancer vaccine (mRNA-based) | Patient-specific neoantigen immunization | Colorectal cancer, lung cancer | Preclinical. Clinical entry targeted as early as early 2027 (Jan 2026 briefing). | Collaboration data with HLB presented at ASCO 2025 | Dealsite; Dailypharm |
Ivaltinostat clinical detail: In Phase 1b, 28 patients with locally advanced or metastatic PDAC who had received at least one prior line of therapy were dosed at 60, 125 and 250 mg/m² (days 1 and 8). Dosing was combined with capecitabine at 1,000 mg/m² twice daily on days 1–14 of each 21-day cycle. No serious adverse events related to ivaltinostat occurred in any cohort (CGP, Jan 2025). The Safety Review Committee set the RP2D at 250 mg/m² (Nov 2023). Under the current dispute, CG Invites reportedly receives no formal notification of trial results from CGP (Dailypharm, May 2026).
Clinical pipeline — anti-infective and inflammation
| Asset | Mechanism | Indication | Stage (per S&P description) |
|---|---|---|---|
| Nilofabicin (CG-549) | FabI inhibitor (bacterial fatty-acid synthesis) | MRSA infections | Phase 1 |
| CG-650 | Anti-inflammatory | Osteoarthritis | Phase 1 |
| CG-651 | Anti-inflammatory | Neuropathic pain | Phase 1 |
| CG-652 | Anti-inflammatory | Rheumatoid arthritis | Phase 1 |
| GSK3 inhibitors | Kinase inhibition | — | Listed by Synapse |
In June 2024 the company said it would concentrate on camrelizumab and ivaltinostat and had halted development of other candidates. Those could resume if circumstances such as research funding changed (Dealsite, Jun 2024). The S&P stage descriptions above may therefore overstate current activity.
Digital healthcare and genomics
Invites Loop (인바이츠 루프)
Description: An AI-based personalized integrated health-management platform. It combines genomic data, health-screening data and lifestyle data to predict health status in real time. AI agents intervene around the clock across prevention, treatment and recovery in a continuous "loop."
Claimed capability: Prediction of 35 chronic diseases, including 11 cancers, with stated accuracy above 83%.
Components: Invites Loop operating system and Integrated Risk Score (IRS) technology.
Commercialization: In Korea, revenue is booked as AI healthcare solutions (KRW 8.2bn in FY2025). In China, an exclusive license to VIDW (Sep 2026) was valued at about USD 6.88M, with a 5% net-sales royalty. In the US, licensing is planned via the New Lake Singapore hub (Jan 2026).
Pricing: Not publicly disclosed.
Genomic analysis / NGS testing services
-
Launched April 2025. CAP accreditation for NGS testing announced May 2025.
-
Revenue: KRW 4.6bn in FY2025, combined with "other."
Digital therapeutics
- Named as a focus area in company descriptions. No named product or regulatory status is disclosed in the sources reviewed.
Non-healthcare product lines
| Product line | FY2025 revenue (KRW Bn) | Detail |
|---|---|---|
| Heating patches (hot packs) | 7.2 | Brand names, manufacturing location and originating entity not disclosed in sources reviewed |
| Automation equipment | 4.7 | Product types and originating entity not disclosed in sources reviewed |
Financial Narrative
All figures are consolidated, from S&P Global Market Intelligence via StockAnalysis.com (financial data last updated 14 Aug 2026; balance sheet as of 31 Mar 2026), unless noted. Ratios are computed by the author from these figures.
Income statement
Dividends: no dividend appears in the data reviewed, and Simply Wall St scores dividends 0/6. This is consistent with the accumulated deficit.
Latest twelve months (TTM to 30 Jun 2026): revenue KRW 30,110M (+185.5% YoY), gross profit −KRW 4,594M, operating income −KRW 24,304M, EBITDA −KRW 17,580M. Net income attributable was +KRW 429M (EPS KRW 5.58). The positive TTM net income came from equity-method gains (KRW 12,887M), a tax credit (KRW 7,923M), losses absorbed by minority interests (KRW 9,178M) and discontinued operations (+KRW 1,748M). Operations remained deeply loss-making.
Margins and growth
Revenue CAGR (computed): FY2021→FY2025 is −10.3% a year, distorted by the Hwail deconsolidation in FY2022. FY2022→FY2025 is +85.1% a year, driven by acquisitions and consolidation.
Commentary:
FY2021–FY2022: The 89.8% revenue drop reflects the end of Hwail Pharmaceutical's consolidation after the 2020–2021 sell-down. Operating losses widened from KRW 6.8bn to KRW 23.1bn once Hwail's profitable API revenue was gone.
FY2023–FY2024: Under New Lake control, losses peaked at KRW 48.9bn (FY2023) and KRW 51.5bn (FY2024) attributable. FY2023 included a KRW 20.7bn loss on sale of investments and KRW 15.8bn of other non-operating losses. FY2024 included KRW 14.4bn of asset writedowns. R&D peaked at KRW 11.3bn in FY2024, equal to 156% of revenue.
FY2025 inflection: Operating loss narrowed by 40% to KRW 23.6bn. SG&A roughly halved (KRW 23.7bn to KRW 12.3bn) and R&D fell 61% to KRW 4.4bn. Within R&D, outsourced research fell 84.9% (KRW 3.6bn to KRW 0.5bn) and R&D personnel cost fell 58.3% (KRW 1.6bn to KRW 0.7bn) (Dailypharm). Attributable net loss narrowed to KRW 3.5bn mainly through below-the-line items. Equity-method income swung from −KRW 5.5bn to +KRW 9.9bn, there was a KRW 7.9bn tax benefit, and KRW 9.0bn of losses were attributed to minority interests.
Quality of earnings: Gross profit is negative and EBITDA remains about −KRW 17bn. The reported improvement in net income is therefore not yet evidence of operating viability.
Balance sheet
Data note: FY2025 total equity (KRW 129,201M) exceeds common equity plus minority interest (KRW 118,675M) by about KRW 10.5bn in the S&P dataset. The difference is unexplained in the source.
Latest interim:
-
31 Mar 2026: total debt KRW 56,944M, of which short-term debt KRW 17,636M and current portion of long-term debt KRW 37,200M. Cash and short-term investments KRW 17,424M. Working capital −KRW 47,271M. Common equity KRW 100,681M (BVPS KRW 1,309).
-
30 Jun 2026: cash and investments KRW 9,391M, total debt KRW 45,438M, net debt KRW 36,047M (S&P via StockAnalysis).
Commentary:
Liquidity erosion: Cash and short-term investments fell 84% from KRW 122.5bn (FY2021) to KRW 19.6bn (FY2025) and KRW 9.4bn (Jun 2026). A KRW 50bn convertible bond was entirely put back early in 2023, according to IB Tomato. Its attribution to CG Invites in that multi-company article should be confirmed against DART.
Debt maturity wall: The entire KRW 37.2bn of long-term debt moved to current liabilities in FY2025, and short-term debt rose to KRW 17.6bn in Q1 2026. Working capital is deeply negative. Simply Wall St flags less than one year of cash runway.
Asset base: Land (KRW 64.2bn) and buildings (KRW 55.1bn) account for most of PP&E. Land rose from KRW 41.7bn to KRW 67.6bn and buildings from KRW 49.9bn to KRW 58.2bn in FY2024. These assets are a potential source of refinancing collateral or sale proceeds.
Acquisitive build-up: Goodwill rose from zero (FY2023) to KRW 3.2bn (FY2024), KRW 7.4bn (FY2025) and KRW 10.3bn (Mar 2026). This corroborates the press accounts of externally incorporated businesses.
Cash flow
TTM to Jun 2026: OCF −KRW 3,361M, capex −KRW 1,263M, FCF −KRW 4,624M. The cash burn has improved materially.
Dividends paid: none recorded in the data reviewed.
Buybacks: A company official told Bizhankook that KRW 8.5bn of shares had been bought since October 2024 to defend the share price. The S&P balance sheet shows zero treasury stock from FY2024 onward.
Funding sources, FY2023–FY2024: Asset disposals funded the cash burn. These included the Pangyo HQ (KRW 34.9bn), the Hwail stake (KRW 12.5bn) and the PanGen stake (KRW 9.3bn). Dailypharm reports total non-core disposals generating KRW 56.8bn of R&D funding.
Ratios (computed, year-end balances)
ROIC: negative throughout, because operating income is negative. The ratio is not meaningful.
Net debt/EBITDA: not meaningful, because EBITDA is negative.
Working-capital ratios: FY2022–FY2024 figures are distorted by tiny revenue bases and year-end consolidation of acquired receivables and inventories. They should not be read as operating trends.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Lines
| Business line (KRW Mn) | FY2025 |
|---|---|
AI healthcare solutions | 8,200 |
Heating patches (hot packs) | 7,200 |
Automation equipment | 4,700 |
Genomic analysis and other | 4,600 |
Arthritis analgesic/anti-inflammatory (Acelex) | 1,700 |
Total consolidated revenue | 27,391 |
Business line share of revenue (%) | FY2025 |
AI healthcare solutions | 30.7 |
Heating patches | 27.1 |
Automation equipment | 17.5 |
Genomic analysis and other | 17.4 |
Acelex | 6.3 |
Revenue by Segment
| Metric (KRW Mn) | FY2025 |
|---|---|
Consolidated revenue | 27,391 |
Standalone (parent) revenue, approx. | 11,800 |
Implied revenue from consolidated subsidiaries, approx. | 15,591 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansGroup Entities
| Entity | Relationship | Status / source |
|---|---|---|
CG Pharmaceuticals, Inc. (Orinda, California, USA) | US clinical subsidiary developing ivaltinostat | CG Invites states it holds 100% and controls the board (Dailypharm, Oct 2024). CGP's own Jan 2025 release describes CGP as an "independent entity" since 2024 after licensing ivaltinostat. Control is contested in US litigation. |
VISTA Invites Digital Ward Limited (VIDW), Hong Kong | Joint venture with VISTA Clinic Limited; licensee of Invites Loop for mainland China | CG Invites is a shareholder (stake not disclosed). Formed 17 Sep 2026 (Dealsite). |
Crystal Bioscience | Subsidiary (100% in 2023) | Dailypharm Aug 2023. |
Macaon Biotherapeutics | Subsidiary (52.3% in 2023) | Dailypharm Aug 2023. |
Invites Ventures (Seoul, founded 2019) | Listed as affiliate/subsidiary | PitchBook. |
BexPharm Healthcare (Seoul, founded 1998) | Listed as affiliate/subsidiary | PitchBook; Citeline. |
Palkion | Listed as related entity | Citeline. |
Guam Regional Medical City (Dededo, Guam) | Management control acquired by CG Invites' largest shareholder (Sep 2025). PitchBook lists it as a subsidiary of CG Invites. | — |
Divested: Hwail Pharmaceutical, PanGen Biotech, Huons Life Sciences (ex-Crystal Life Sciences) | Former affiliates/subsidiaries | Fully exited 2023–2024 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Mn) | 42,376 | 4,321 | 4,879 | 7,253 | 27,391 |
Revenue growth (%) | 40.2 | -89.8 | 12.9 | 48.7 | 277.6 |
Cost of revenue (KRW Mn) | 20,669 | 3,066 | 3,422 | 7,772 | 29,333 |
Gross profit (KRW Mn) | 21,707 | 1,256 | 1,457 | -519 | -1,941 |
SG&A (KRW Mn) | 19,770 | 16,956 | 22,629 | 23,670 | 12,299 |
R&D expense (KRW Mn) | 4,859 | 6,305 | 7,182 | 11,318 | 4,424 |
Amortization of goodwill and intangibles (KRW Mn) | 1,381 | 175 | 174 | 718 | 1,783 |
Operating income (KRW Mn) | -6,846 | -23,092 | -32,119 | -39,178 | -23,614 |
D&A for EBITDA (KRW Mn) | 2,995 | 3,480 | 3,199 | 4,250 | 6,608 |
EBITDA (KRW Mn) | -3,851 | -19,613 | -28,920 | -34,928 | -17,006 |
Interest expense (KRW Mn) | 2,435 | 1,068 | 2,095 | 3,478 | 4,269 |
Interest and investment income (KRW Mn) | 2,691 | 1,800 | 2,421 | 1,194 | 2,581 |
Equity-method earnings (KRW Mn) | -11,511 | -250 | -4,002 | -5,503 | 9,944 |
Gain or loss on sale of investments (KRW Mn) | 4,579 | -1,953 | -20,712 | 4,113 | 2,515 |
Asset writedowns (KRW Mn) | -509 | 0 | -4 | -14,351 | -6,966 |
Pre-tax income (KRW Mn) | -15,617 | -22,743 | -51,152 | -50,062 | -20,433 |
Income tax expense (KRW Mn) | 2,723 | 615 | -2,941 | 1,747 | -7,921 |
Net income to company (KRW Mn) | -18,340 | -25,568 | -50,042 | -51,809 | -12,512 |
Losses attributed to minority interests (KRW Mn) | 2,440 | 1,699 | 1,118 | 265 | 8,991 |
Net income attributable to parent (KRW Mn) | -15,901 | -23,869 | -48,924 | -51,544 | -3,521 |
EPS basic (KRW) | -232.20 | -344.84 | -661.31 | -671.00 | -45.85 |
EPS diluted (KRW) | -232.20 | -345.00 | -661.31 | -671.00 | -45.85 |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Weighted average shares (M) | 68 | 69 | 74 | 77 | 77 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 51.2 | 29.1 | 29.9 | -7.2 | -7.1 |
Operating margin (%) | -16.2 | -534.4 | -658.4 | -540.1 | -86.2 |
EBITDA margin (%) | -9.1 | -453.9 | -592.7 | -481.6 | -62.1 |
Pre-tax margin (%) | -36.9 | -526.3 | -1,048.5 | -690.2 | -74.6 |
Net margin (%) | -37.5 | -552.4 | -1,002.8 | -710.6 | -12.9 |
FCF margin (%) | -52.1 | -903.4 | -1,140.6 | -482.4 | -73.3 |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (KRW Mn) | 332,927 | 322,613 | 243,116 | 260,465 | 224,109 |
Cash and equivalents (KRW Mn) | 30,955 | 29,964 | 23,011 | 42,933 | 11,584 |
Short-term investments (KRW Mn) | 31,606 | 29,417 | 28,224 | 1,812 | 872 |
Trading securities (KRW Mn) | 59,939 | 22,653 | 174 | 8,819 | 7,144 |
Cash and short-term investments (KRW Mn) | 122,500 | 82,033 | 51,410 | 53,564 | 19,599 |
Receivables (KRW Mn) | 12,318 | 9,324 | 2,824 | 11,699 | 18,295 |
Inventory (KRW Mn) | 8,578 | 5,677 | 1,555 | 9,181 | 6,418 |
Total current assets (KRW Mn) | 144,965 | 98,854 | 56,652 | 75,802 | 45,865 |
PP&E (KRW Mn) | 86,371 | 100,174 | 95,590 | 133,246 | 126,936 |
Long-term investments (KRW Mn) | 79,375 | 90,427 | 79,915 | 26,319 | 29,718 |
Goodwill (KRW Mn) | 2,026 | 2,026 | 0 | 3,235 | 7,392 |
Other intangibles (KRW Mn) | 8,120 | 6,405 | 1,680 | 5,474 | 9,195 |
Short-term debt (KRW Mn) | 46,348 | 48,806 | 7,120 | 6,900 | 6,890 |
Current portion of long-term debt (KRW Mn) | 3,729 | 652 | 1,960 | 4,000 | 37,200 |
Long-term debt (KRW Mn) | 24,005 | 20,282 | 29,738 | 42,200 | 0 |
Lease liabilities total (KRW Mn) | 641 | 458 | 305 | 357 | 2,371 |
Total debt (KRW Mn) | 74,723 | 70,199 | 39,123 | 53,457 | 46,461 |
Net debt (KRW Mn) | -47,777 | -11,835 | -12,287 | -107 | 26,861 |
Total current liabilities (KRW Mn) | 66,513 | 58,526 | 55,548 | 71,179 | 78,942 |
Total liabilities (KRW Mn) | 118,301 | 106,880 | 97,823 | 130,909 | 94,908 |
Total common equity (KRW Mn) | 207,838 | 188,276 | 145,293 | 98,518 | 105,153 |
Minority interest (KRW Mn) | 6,789 | 5,147 | 0 | 22,281 | 13,522 |
Total shareholders' equity (KRW Mn) | 214,626 | 215,733 | 145,293 | 129,556 | 129,201 |
Working capital (KRW Mn) | 78,452 | 40,328 | 1,104 | 4,623 | -33,077 |
Book value per share (KRW) | 3,072 | 2,732 | 1,898 | 1,281 | 1,368 |
Tangible book value per share (KRW) | 2,922 | 2,610 | 1,876 | 1,168 | 1,152 |
Cash Flow and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW Mn) | -11,458 | -24,405 | -32,408 | -25,850 | -17,413 |
Capital expenditure (KRW Mn) | -10,607 | -14,632 | -23,236 | -9,138 | -2,671 |
Free cash flow (KRW Mn) | -22,065 | -39,037 | -55,644 | -34,988 | -20,084 |
FCF per share (KRW) | -322.22 | -563.98 | -752.15 | -455.48 | -261.52 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE on year-end common equity (%) | -7.7 | -12.7 | -33.7 | -52.3 | -3.3 |
ROA on year-end total assets (%) | -4.8 | -7.4 | -20.1 | -19.8 | -1.6 |
Current ratio (x) | 2.18 | 1.69 | 1.02 | 1.06 | 0.58 |
Debt to total equity (x) | 0.35 | 0.33 | 0.27 | 0.41 | 0.36 |
Interest coverage, EBIT/interest (x) | -2.8 | -21.6 | -15.3 | -11.3 | -5.5 |
Asset turnover (x) | 0.13 | 0.01 | 0.02 | 0.03 | 0.12 |
Days sales outstanding (days) | 86 | 628 | 11 | 470 | 123 |
Days inventory outstanding (days) | 151 | 676 | 166 | 431 | 80 |
Days payables outstanding (days) | 37 | 221 | 461 | 194 | 17 |
Cash conversion cycle (days) | 200 | 1,083 | -284 | 707 | 186 |
Capital Markets
| Metric | 1Y | 3Y | 5Y |
|---|---|---|---|
Share price change (%) | -41.55 | -66.98 | -86.56 |
Price Point Details
| Price point | Value (KRW) | Date | Source |
|---|---|---|---|
52-week high | 1,667 | Trailing as of snapshot | Simply Wall St |
52-week low | 711 | Trailing as of snapshot | Simply Wall St |
Close | 761 | 19 Aug 2026 | StockAnalysis |
Close | 885 | 25 Aug 2026 (YTD −40.48%) | MarketScreener |
Close | 953 | 11 Sep 2026 | StockAnalysis |
Close | 873 | 15 Oct 2026 | StockAnalysis |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market capitalization | KRW 67.1bn | 76.89M shares × KRW 873 |
Enterprise value | About KRW 115.3bn | Market cap + debt KRW 45.4bn (Jun 2026) − cash and investments KRW 9.4bn (Jun 2026) + minority interest KRW 12.2bn (Mar 2026) |
P/E (TTM) | About 156x; not meaningful | TTM EPS KRW 5.58 is driven by non-operating items |
EV/Sales (TTM) | About 3.8x | TTM revenue KRW 30.1bn |
P/S (current) | 2.23x | StockAnalysis |
P/B | About 0.67x | Q1 2026 BVPS KRW 1,309 |
P/TBV | About 0.80x | Q1 2026 TBVPS KRW 1,093 |
Capital Markets — Analyst consensus
| Item | Status |
|---|---|
Analyst consensus | No sell-side coverage identified. Simply Wall St shows no future-growth estimates (score 0/6). |
Dividend history and policy | No dividends paid in FY2021–FY2025 in the data reviewed; no stated dividend policy |
Buyback authorizations | No formal authorization identified. |
Bonus issue | 50% bonus share issue decided Dec 2022 (IRGO) |
Reverse split | Considered by the market; ruled out by CEO (Jun 2026) |
Credit ratings | No Moody's, S&P or Fitch ratings. Domestic ratings not identified. |
Debt maturity profile | All long-term borrowings (KRW 37.2bn) fall due within 12 months of 31 Dec 2025; short-term debt KRW 17.6bn (Mar 2026). Instrument-level detail (bank loans vs. bonds, rates, collateral) not publicly disclosed in sources reviewed. |
Shares outstanding trend | 67.65M (FY2021), 68.91M (FY2022), 76.54M (FY2023), 76.89M (FY2024–Q1 2026). The FY2023 increase reflects the New Lake rights offering. |
Analyst Conclusions
Management guidance
-
No quantitative guidance.
-
Qualitative expectations: digital-healthcare monetization from H2 2026 (CEO, Jun 2026); revenue and operating-profit improvement from China royalties (company, Sep 2026); vaccine clinic entry as early as early 2027; long-term enterprise-value aspiration of KRW 1 trillion.
Consensus
None. The stock has no identified sell-side coverage.
Bull case
-
Platform royalties scale. VIDW gives Invites Loop access to VISTA's Beijing and Shenzhen clinics, about 30 corporate medical sites and about 60 insurers, in a China market growing 24.7% a year. A 5% royalty on a successful roll-out, plus US licensing via Singapore, could create high-margin revenue that the current KRW 30bn revenue base does not reflect.
-
Asset backing caps the downside. The stock trades at about 0.67x book and about 0.80x tangible book. Land and buildings of about KRW 119bn exceed the market capitalization of about KRW 67bn, so monetizing real estate could resolve the debt maturity wall without dilution.
-
Ivaltinostat optionality. A positive Phase 2 PFS readout in PDAC maintenance, where no HDAC inhibitor is approved, would re-rate the oncology pipeline. That would require a settlement that restores CG Invites' economic claim on CGP.
Bear case
-
Liquidity forces dilution. With KRW 9.4bn of cash against about KRW 45bn of debt and negative working capital of −KRW 47bn, a sizable rights issue or asset fire sale is likely within 12 months. That would further erode a share price already down 86.6% over five years.
-
Operating economics are unproven. Consolidated gross margin is negative (−15.3% TTM) and EBITDA is about −KRW 17.6bn. Reported profit improvements come from equity-method gains, tax credits and minority interests rather than from operations.
-
The drug-development franchise has been hollowed out. R&D is down 61%, luxeptinib has been returned or deprioritized, other candidates are halted, and the lead asset is controlled in practice by a litigant. What remains is a marginal NSAID (KRW 1.7bn in sales) and a Korean bridging study for a crowded PD-1 market.
Key catalysts and monitorables (next 12 months)
| Catalyst | Timing | Why it matters |
|---|---|---|
| Upcoming EGM (e-voting notice 28 Sep 2026) | Q4 2026 | Agenda may involve capital raising, business-purpose changes or a merger. |
| Refinancing of KRW 37.2bn current borrowings | Through 2026 | Determines whether dilution or asset sales are needed |
| First royalty revenue from VIDW | From Q4 2026 / 2027 | First proof that the platform model works |
| US court developments in the Cho/CGP case | Ongoing | Sets control and economics of ivaltinostat |
| Ivaltinostat Phase 2 PDAC data (NCT05249101) | Timing not disclosed | Binary pipeline value event |
| Camrelizumab Korean bridging study progress | 2026–2027 | Possible Korean filing pathway |
| Acelex Russia export contract | — | Revenue for the legacy product |
| Cancer vaccine IND / clinic entry | As early as early 2027 | Pipeline replenishment |
| Gross-margin trajectory of the consolidated businesses | Quarterly | Core test of the transformation |
| Related-party dealings with Invites ecosystem entities (GRMC, New Lake Singapore) | Ongoing | Governance and value-transfer risk |
Analyst verdict
CG Invites is no longer the company its listing history suggests. The first technology-track biotech on KOSDAQ and the developer of Korea's 22nd domestic new drug has been reconfigured since mid-2023 by its private-equity owner, New Lake Alliance. It is now a mixed portfolio. AI health solutions, heating patches, automation equipment and genomic testing produced about 92% of FY2025 revenue, while prescription drugs produced about 6%. This reconfiguration has achieved two things. Revenue has scaled to about KRW 30bn on a trailing basis, and cash burn has fallen sharply, with trailing free cash flow of about −KRW 4.6bn against −KRW 55.6bn in FY2023.
It has not yet produced an economically self-sustaining business. Consolidated gross margins are negative. EBITDA losses persist at about KRW 17–18bn a year. The improvement in net income relies on non-operating items. The balance sheet is the immediate constraint. Cash of KRW 9.4bn, KRW 37.2bn of long-term borrowings now current, and working capital of about −KRW 47bn mean that funding decisions in the coming quarters will largely determine shareholder outcomes. The large land and building base, worth more than the equity market value, is the main mitigant. Using it to refinance or sell assets would be preferable to dilutive issuance.
Strategically, the September 2026 China license is the first concrete external validation of the Invites Loop platform. Its modest upfront valuation (about USD 6.88M) and royalty-only upside mean it is a proof point, not yet a value driver. The oncology pipeline holds the most asymmetric upside in ivaltinostat, but that value is impaired by the unresolved US dispute with the founder.
Verdict: The stock is a high-risk, special-situation holding. A low price-to-book multiple sits alongside a credible risk of dilution and unproven unit economics. Conviction should await evidence of positive gross margins and a funded balance sheet.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / notes | Background | Source |
|---|---|---|---|---|
Lee Ho-young (이호영) | CEO (대표이사) | Referred to as President in May 2025 and as CEO from Jan 2026 | Prior roles, education and age not disclosed in sources reviewed | Financial News; Dealsite |
Oh Soo-yeon (오수연) | Co-CEO (appointed Mar 2024) | Concurrently Vice President of Invites BioCore. | PhD in pharmacology (Dankook University); former principal researcher at Bio Infra; former operations head at Xenia | Dealsite (Jul 2025) |
Park Yi-geun (박이근) | Executive Director (전무) | Presented the Jan 2026 shareholder briefing | — | Dealsite |
Cho Yoon-sung (조윤성) | Chief Technology Officer | Leads the cancer vaccine program | — | Dealsite |
CFO | Name not disclosed in sources reviewed | Bought about 20,000 shares in Nov 2024 | — | Dailypharm |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Stake | Notes |
|---|---|---|
Insiders | Co-CEO and CFO each bought about 20,000 shares (Nov 2024) | Total insider ownership not disclosed |
Competitive Landscape
Competitors by Segment
| Business line | Named competitors | Notes |
|---|---|---|
Pancreatic cancer drug development (Korea-origin) | NeoImmuneTech (NT-I7), MedPacto (vactosertib), Prestige Biopharma (PBP1510), GC Cell (Immuncell-LC combination) | Dailypharm names these as Korean pancreatic-cancer developers alongside CG Invites |
HDAC inhibitors (global) | Approved HDAC inhibitors such as vorinostat, romidepsin, belinostat and panobinostat (hematologic indications) | No HDAC inhibitor is approved in PDAC; ivaltinostat's differentiation is in PDAC maintenance |
PD-1 in Korean NSCLC | Merck & Co. (Keytruda), BMS/Ono (Opdivo), Roche (Tecentriq, PD-L1), BeiGene (tislelizumab) | Camrelizumab would enter a mature, crowded checkpoint market |
Osteoarthritis NSAIDs (Korea) | Pfizer/Viatris (Celebrex, celecoxib) and numerous celecoxib generics; traditional NSAIDs | Acelex sales (KRW 1.7bn) indicate marginal share |
Genomics / NGS services (Korea) | Macrogen, GC Genome, EDGC, Theragen Bio | Established domestic players |
AI healthcare / medical AI (Korea) | Lunit, VUNO, Kakao Healthcare (unlisted) | Larger, better-funded AI-health specialists |
Heating patches, automation equipment | Not identified in sources reviewed | — |
Competitor Detail
| Metric (latest FY) | CG Invites (FY2025) |
|---|---|
Revenue (KRW Bn) | 27.4 |
Revenue growth (%) | 277.6 |
Operating margin (%) | -86.2 |
R&D intensity (% of revenue) | 16.2 |



